These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 11326679

  • 1. The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer.
    Micke O, Prott FJ, Schäfer U, Tangerding S, Pötter R, Willich N.
    Anticancer Res; 2000; 20(6D):5113-5. PubMed ID: 11326679
    [Abstract] [Full Text] [Related]

  • 2. The impact of squamous cell carcinoma (SCC) antigen in patients with advanced cancer of uterine cervix treated with (chemo-)radiotherapy.
    Micke O, Bruns F, Schäfer U, Prott FJ, Willich N.
    Anticancer Res; 2005; 25(3A):1663-6. PubMed ID: 16033078
    [Abstract] [Full Text] [Related]

  • 3. [Impact of squamous cell carcinoma antigen in patients with recurrent squamous cell carcinoma of the uterine cervix].
    Ma SK, Wu LY, Sun YC, Li B, Zhang HT.
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):13-7. PubMed ID: 18366925
    [Abstract] [Full Text] [Related]

  • 4. Measurement of serum squamous cell carcinoma antigen levels as a predictor of radiation response in patients with carcinoma of the uterine cervix.
    Ohno T, Nakayama Y, Nakamoto S, Kato S, Imai R, Nonaka T, Ishikawa H, Harashima K, Suzuki Y.
    Cancer; 2003 Jun 15; 97(12):3114-20. PubMed ID: 12784349
    [Abstract] [Full Text] [Related]

  • 5. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer.
    Reesink-Peters N, van der Velden J, Ten Hoor KA, Boezen HM, de Vries EG, Schilthuis MS, Mourits MJ, Nijman HW, Aalders JG, Hollema H, Pras E, Duk JM, van der Zee AG.
    J Clin Oncol; 2005 Mar 01; 23(7):1455-62. PubMed ID: 15735121
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [SCC (squamous cell carcinoma) antigen as a tumor marker in cervix cancers].
    Geyer H, Schwörer D, Pfleiderer A.
    Geburtshilfe Frauenheilkd; 1989 Mar 01; 49(3):266-71. PubMed ID: 2721888
    [Abstract] [Full Text] [Related]

  • 8. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
    Gadducci A, Tana R, Cosio S, Genazzani AR.
    Crit Rev Oncol Hematol; 2008 Apr 01; 66(1):10-20. PubMed ID: 17964182
    [Abstract] [Full Text] [Related]

  • 9. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer.
    Kainz C, Sliutz G, Mustafa G, Bieglmayr C, Koelbl H, Reinthaller A, Gitsch G.
    Gynecol Oncol; 1995 Mar 01; 56(3):402-5. PubMed ID: 7535720
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen.
    Tsai SC, Kao CH, Wang SJ.
    Neoplasma; 1996 Mar 01; 43(1):27-9. PubMed ID: 8843956
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Experiences with the squamous cell carcinoma antigen, a new tumor marker for cancer of the uterine cervix].
    Meier W, Eiermann W, Stieber P, Fateh-Moghadam A, Hepp H.
    Geburtshilfe Frauenheilkd; 1989 Jul 01; 49(7):625-9. PubMed ID: 2777050
    [Abstract] [Full Text] [Related]

  • 14. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix.
    Bolli JA, Doering DL, Bosscher JR, Day TG, Rao CV, Owens K, Kelly B, Goldsmith J.
    Gynecol Oncol; 1994 Nov 01; 55(2):169-73. PubMed ID: 7959279
    [Abstract] [Full Text] [Related]

  • 15. Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC).
    Hung YC, Shiau YC, Chang WC, Kao CH, Lin CC.
    Neoplasma; 2002 Nov 01; 49(6):415-7. PubMed ID: 12584591
    [Abstract] [Full Text] [Related]

  • 16. Clinical evaluation of serum and immunohistochemical expression of SCC and CA19-9 in radiation therapy for cervical cancer.
    Abe A, Nakano T, Morita S, Oka K.
    Anticancer Res; 1999 Nov 01; 19(1B):829-36. PubMed ID: 10216501
    [Abstract] [Full Text] [Related]

  • 17. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix.
    Duk JM, Aalders JG, Fleuren GJ, Krans M, De Bruijn HW.
    Obstet Gynecol; 1989 Apr 01; 73(4):661-8. PubMed ID: 2648225
    [Abstract] [Full Text] [Related]

  • 18. Biochemical prognostic factors and risk of relapses in patients with cervical cancer.
    Gadducci A, Tana R, Fanucchi A, Genazzani AR.
    Gynecol Oncol; 2007 Oct 01; 107(1 Suppl 1):S23-6. PubMed ID: 17727924
    [Abstract] [Full Text] [Related]

  • 19. [Determination of the SCC antigen in the serum of patients with cervical cancer].
    Crombach G, Würz H, Bolte A.
    Geburtshilfe Frauenheilkd; 1987 Jul 01; 47(7):439-45. PubMed ID: 3623046
    [Abstract] [Full Text] [Related]

  • 20. [The importance of the SCC antigen in the diagnosis and follow-up of cervix carcinoma. A cooperative study of the Gynecologic Tumor Marker Group (GTMG)].
    Crombach G, Würz H, Herrmann F, Kreienberg R, Möbus V, Schmidt-Rhode P, Sturm G, Caffier H, Kaesemann H.
    Dtsch Med Wochenschr; 1989 May 05; 114(18):700-5. PubMed ID: 2714197
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.